Skip to main content

J3247: Permanent J-code for the IV formulation of COSENTYX®*

Effective July 1, 2024, for all sites of care

*If COSENTYX is administered on or after July 1, 2024, the permanent J-code replaces the miscellaneous J-code J3590.
It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient. Novartis cannot guarantee insurance coverage or reimbursement. 

Reference: CMS, HCPCS Quarterly Update, April 2024.

desktop home psa manifestations
*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms and Conditions details, call 1-844-267-3689.